Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks compared with patients receiving standard of ...
Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity and remission, and more time spent in those states, vs. standard therapy ...
The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...
THURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE ...